We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Acute kidney injury: emerging pharmacotherapies in current clinical trials.
- Authors
Benoit, Stefanie Woolridge; Devarajan, Prasad
- Abstract
Acute kidney injury (AKI) is a significant source of morbidity and mortality in pediatric patients, affecting more than one quarter of critically ill children. Despite significant need, there are no targeted therapies to reliably prevent or treat AKI. Recent advances in our understanding of renal injury and repair signaling pathways have enabled the development of several targeted pharmaceuticals. Here we review emerging pharmacotherapies for AKI that are currently in clinical trials. Categorized by their general mechanism of action, the therapies discussed include anti-inflammatory agents (recAP, AB103, ABT-719), antioxidants (iron chelators, heme arginate), vasodilators (levosimendan), apoptosis inhibitors (QPI-1002), and repair agents (THR-184, BB-3, mesenchymal stem cells).
- Subjects
ANTI-inflammatory agents; EVALUATION of clinical trials; KIDNEY disease prevention; KIDNEY injuries; ANTIOXIDANTS; APOPTOSIS; CELLULAR signal transduction; DRUG therapy; CRITICALLY ill; DISEASES; IRON; KIDNEY diseases; PATIENTS; PEDIATRICS; STEM cells; VASODILATORS; ACUTE diseases; CHELATING agents
- Publication
Pediatric Nephrology, 2018, Vol 33, Issue 5, p779
- ISSN
0931-041X
- Publication type
Article
- DOI
10.1007/s00467-017-3695-3